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ABSTRACT
Background: Hepatocellular carcinomas (HCCs) expressing stemness markers 
are characterized by an aggressive behavior, which might be promoted by an altered 
tumor stroma. Transarterial chemoembolization (TACE) induces severe hypoxia, and 
its effect on stemness and tumor stroma of HCCs remains unclear. The purpose of this 
study was to evaluate the sequential changes of stemness and tumor stroma under 
TACE-induced hypoxia using biopsy and resection-matched HCCs.
Methods: Forty-six biopsy and resection matched HCCs including 10 cases with 
and 36 cases without preoperative TACE were selected. Immunohistochemistry 
for stemness (keratin 19 [K19], epithelial cell adhesion molecule [EpCAM], and 
CD133), hypoxia (carbonic anhydrase IX [CAIX] and vascular endothelial growth 
factor [VEGF]), and tumor stromal (α-smooth muscle actin [α-SMA] and fibroblast 
activation protein [FAP]) markers were performed and compared in matched biopsied 
and resected HCCs with and without TACE.
Results: The accuracy of K19, EpCAM, CD133, CAIX, VEGF, α-SMA and FAP 
detected on biopsied HCCs was 64% ~ 86%, using the expression status in resected 
HCCs as a reference standard in non-TACE group. The sequential change of hypoxia, 
stemness and stromal marker expression in matched biopsied and resected HCC 
was greater in TACE group than in non-TACE group (P < 0.05 for all). The degree 
of stemness marker expression was well correlated with those of tumor stromal 
markers, and the degree of CAIX expression was well correlated with that of K19  
(P < 0.05). 
Conclusions: Stemness marker expression is considered to be increased along 
with tumor stromal alteration under TACE-induced hypoxia, which might promote the 
aggressive biology of HCC.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the seventh 
most common malignancy worldwide, and the third 
greatest cause of cancer related mortality, especially 
in Asia and sub-Saharan Africa [1, 2]. Transarterial 
chemoembolization (TACE) is a popular loco-regional 
therapy in downstaging or bridging to make curative 
treatments (e.g. resection, transplantation) of HCC 
possible [3]. Although TACE induces marked tumor 
necrosis by obstructing tumor-feeding arteries with 
chemotherapy emulsioned with lipiodol and embolic 
agents [4, 5], a significant number (27 ~ 72%) of HCCs 
show residual viable tumor after TACE [6]. 
Cancer stem cells (CSCs), characterized by their 
ability to self-renew and propagate tumors, play an 
important role in tumor maintenance and recurrence 
[7, 8]. HCCs expressing stemness-related markers, such 
as keratin 19 (K19), epithelial cell adhesion molecule 
(EpCAM), or CD133, are reportedly associated with an 
aggressive biological behavior with poorer prognosis, 
compared to HCCs not expressing these markers [9–11]. 
Hypoxia has been found to be involved in maintenance of 
CSCs of several cancers, including HCC, glioblastoma, 
breast cancer, and hematologic malignancies [12–15]. 
Recently, increased expression of stemness-related 
markers was reported in resected/explanted HCCs after 
TACE treatment [16, 17]. 
The biological behavior of tumors is reportedly 
determined by not only tumoral epithelial cells themselves 
but also by the tumor stroma, which is a complicated 
system composed of extracellular matrix proteins, 
proteolytic enzymes, blood vessels, and a variety of 
cellular components, including cancer-associated 
fibroblasts (CAFs) and immune cells, etc [18–21]. 
CAFs, histologically categorized as myofibroblasts or 
activated fibroblasts, were also reported to be associated 
with aggressive biological behavior, poor prognosis, 
and resistance to chemotherapy and radiation therapy in 
several tumors including HCC [22–25]. HCCs usually 
contain no or only a little amount of fibrous stroma; 
nevertheless, we previously reported that HCCs with 
stemness markers showed tumor stroma [9]. Interestingly, 
explanted HCCs after TACE were reported to be more 
fibrotic than those without [16]. 
Therefore, TACE-induced hypoxia might modulate 
stemness and tumor stroma of HCC, which are associated 
with poor clinical outcomes. However, the sequential 
changes in the expression of stemness markers and tumor 
stroma of HCCs after TACE remain unclear. In this study, 
we first checked whether the immunoprofiles of biopsied 
HCCs, which contain only small portions of tumor, 
can represent those of whole tumor, by comparing the 
immunoprofiles of stemness (K19, EpCAM, and CD133), 
hypoxia (carbonic anhydrase IX [CAIX] and vascular 
endothelial growth factor [VEGF]), and tumor stromal 
markers (α-smooth muscle actin [α-SMA] and fibroblast 
activation protein [FAP]) between matched biopsied and 
resected HCCs in non-TACE group. Then the sequential 
changes in the expression status of stemness, hypoxia, and 
tumor stromal markers were evaluated by comparing the 
change in expression status of these markers in matched 
preoperative biopsied and resected HCCs, between HCCs 
with preoperative TACE and those without. 
RESULTS
Comparison of the immunoprofiles between 
matched preoperative biopsies and resected 
HCCs
To investigate whether the immunoprofiles of 
biopsied HCC tissue may represent those of the whole 
tumor in resected HCCs, we compared the expression 
status of stemness-, hypoxia- and stromal- markers 
between matched preoperative baseline biopsies and 
the resected HCCs in the non-TACE group (n = 36) 
(Figure 1). Only the non-TACE group was analyzed in 
order to exclude the possible effects of preoperative TACE 
on the immunoprofiles of resected HCCs. No significant 
differences were found in the degrees of K19, EpCAM, 
CD133, CAIX, VEGF, α-SMA and FAP expression 
between biopsied and resected HCC tissues (Figure 1B). 
In addition, the diagnostic performance of 
immunohistochemical result based on biopsied 
HCCs was evaluated using the immunoprofiles of 
resected HCCs as a standard of reference, and the 
expression status of each marker was checked as binary 
classification (i.e. negative and positive). The accuracy of 
immunohistochemical stains on biopsies was 86%, 78% 
and 78% for K19, EpCAM, and CD133, respectively, 
and 72%, 81%, 72% and 64% for CAIX, VEGF, α-SMA 
and FAP, respectively (Table 1). Taken together, the 
immunoprofiles of biopsied HCCs may represent those 
of resected HCCs. 
The sequential change in the expression of 
stemness, hypoxia and stromal markers after 
TACE 
No significant differences were seen in the 
expression status of K19, EpCAM, CD133, CAIX, VEGF, 
α-SMA and FAP in the preoperative baseline biopsied 
HCCs between the TACE and non-TACE groups. In 
contrast, for resected HCCs, the incidence of EpCAM and 
α-SMA expression was significantly higher in HCCs with 
preoperative TACE than in those without (P < 0.05 for 
both). The clinicopathological features of resected HCCs 
with and without preoperative TACE are summarized 
in Table 2. The resected HCCs with preoperative TACE 
showed younger age, poorer differentiation of HCC, 
higher incidence and greater extents of tumor necrosis, 
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compared to those without preoperative TACE (P < 0.05 
for all). Other clinicopathological features of resected 
HCCs, including TNM stage showed no significant 
difference between the two groups.
The sequential change in the degree of 
immunoexpression between biopsied and resected 
HCCs was evaluated and compared between HCCs with 
preoperative TACE and those without. The sum of score 
change in three stemness markers (K19, EpCAM, and 
CD133) showed a significant difference between HCCs 
with preoperative TACE and those without (P = 0.031), 
indicating an increased expression of stemness markers 
after TACE (Figure 2A). The sum of score change in 
hypoxia markers (CAIX and VEGF) showed a significant 
difference between HCCs with preoperative TACE 
and those without (P = 0.046), indicating an increased 
hypoxic tumor microenvironment after TACE (Figure 2B). 
Similarly, the sum of score change in stromal markers 
(α-SMA and FAP) showed a significant difference 
between HCCs with preoperative TACE and those without 
(P = 0.047), suggesting an altered tumor stroma after 
TACE (Figure 2C). 
The relationship of stemness marker expression with 
those for tumor stroma and hypoxia was evaluated in all 
resected HCCs including TACE and non-TACE groups 
(n = 46) (Figure 2D). The degree of K19 and EpCAM 
expression was well correlated with tumor stromal FAP 
expression (P = 0.042 and P = 0.004, respectively), and 
the degree of CD133 expression was well correlated with 
tumor stromal α-SMA expression (P = 0.005). The degree 
Figure 1: (A) Hepatocellular carcinoma showing expression of K19, EpCAM, CD133, CAIX and VEGF in tumoral epithelial cells and 
expression of α-SMA and FAP in tumoral stromal cells in matched biopsied and resected HCC without preoperative TACE. The photos 
of H-E, K19, EpCAM, CAIX and VEGF were taken from case number 1, those of CD133 and α-SMA were taken from case number 
13, and those of FAP were taken from case number 18. (B) A summary of the immunoprofiles in the matched preoperative biopsied and 
resected HCCs without preoperative TACE. The cases with high expression, low expression, and negative expression are indicated by 
black, gray and white boxes, respectively.
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of CAIX expression was well correlated with that of K19 
expression (P = 0.007), but not for those of EpCAM 
and CD133 (P > 0.05 for both). The degree of VEGF 
expression was not correlated with any stemness marker 
of K19, EpCAM and CD133 (P > 0.05 for all).
The prognostic significance of stemness, hypoxia 
and stromal marker expression in biopsied and 
resected HCCs in non-TACE group
The prognostic significance of clinicopathologic 
features, and expression of stemness, hypoxia and 
stromal markers was evaluated in non-TACE group to 
exclude the effect of TACE on HCCs. In the preoperative 
biopsied HCCs of the non-TACE group, univariate 
analysis of immunoprofiles performed on biopsied HCCs 
revealed that expression of K19 (P = 0.011), CAIX 
(P = 0.023), VEGF (P = 0.039) and α-SMA (P = 0.045) 
were adverse prognostic factors for overall survival (Table 3, 
Figure 3A). Other immunomarkers (including EpCAM, 
CD133 and FAP), and other preoperatively collected clinical 
data (including age, gender, etiology and serum markers) 
showed no significant impact on overall survival. 
The pathological features of resected non-
TACE group HCCs were also evaluated for the overall 
survival, and the expression of K19, CAIX and FAP, and 
microvascular invasion, and TNM stage were significant 
for poor overall survival (P < 0.05 for all). (Table 3, 
Figure 3B). Multivariate analysis for overall survival 
was performed using five postoperatively collected 
factors (K19, CAIX, and FAP expression, microvascular 
invasion and TNM stage). CAIX and FAP expression 
showed statistical significance (P = 0.001 and P = 0.022, 
respectively) for overall survival (Table 4).
DISCUSSION
Hypoxia can modulate tumor biology by 
activation of hypoxia adaptation pathways, especially 
hypoxia inducible factor-1 (HIF-1) [3, 12, 26]. CAIX, 
a direct transcriptional target of HIF-1α, is considered 
an endogenous marker for the transcriptional activity 
of HIF-1α [27, 28], and can be more easily detected 
by immunohistochemical stain than HIF-1α, which 
has a short half-life (<5 min) [29]. VEGF expression 
is also induced by hypoxia response genes including 
HIF-1α, and promotes neovascularization [30]. 
Recently, hypoxia has been reported to be important 
in reprogramming to cancer stem cell phenotype and 
maintenance of cancer stem cells in several cancer 
types, including HCC [12–15, 31, 32], and increased 
expression of stemness markers was reported in 
resected/explanted HCCs after TACE treatment [16, 
17]. We also reported that the expression of K19, 
EpCAM and CAIX was significantly higher in residual 
viable HCCs with preoperative TACE compared to 
those without, and that K19, EpCAM, and CAIX were 
more frequently expressed in HCCs with a greater 
number of TACE sessions, suggesting that evaluation 
of these markers in biopsied HCC tissue might have an 
additional value in predicting HCC outcome, especially 
for TACE-treated cases [33]. 
To address the question of whether the 
immunoprofiles of small needle biopsy tissues are 
representative of the whole tumor, we compared the 
expression status of stemness-, hypoxia- and tumor 
stroma-related markers in matched preoperative biopsied 
and resected HCC tissues without TACE. Using the 
immunoprofiles of the resected HCCs as a standard of 
reference, the accuracies of marker expression ranged 
from 64% to 86%, suggesting that the immunoprofiles of 
biopsied HCCs could be considered to be representative 
of whole HCCs. A gene expression analysis study on 
different areas of the same tumor demonstrated little 
differences in the gene expression profiles according to 
the location [34]. In addition, the expression of K19 and 
CAIX in biopsied HCC tissues as well as their expression 
in resected HCCs was significant for poor overall survival 
in this study.
Table 1: Sensitivity, specificity, and accuracy of immunoexpression detected in the baseline preoperative biopsied 
HCCs using the immunoprofiles of resected HCCs as standard of references in non-TACE group (n = 36)
Immunomarkers Sensitivity Specificity Accuracy
K19 80% 88% 86%
EpCAM 64% 86% 78%
CD133 71% 82% 78%
CAIX 50% 81% 72%
VEGF 86% 57% 81%
α-SMA 89% 53% 72%
FAP 65% 63% 64%
Abbreviations: K19, keratin 19; EpCAM, epithelial cell adhesion molecule; CAIX, carbonic anhydrase IX; VEGF, vascular 
endothelial growth factor; α-SMA, α-smooth muscle actin; FAP, fibroblast activation protein.
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Table 2: Clinicopathological features of HCCs in the TACE group and non-TACE group 
Clinicopathological features TACE group (n = 10) non-TACE group (n = 36) P value
Age (year, median, IQR) 52.0 (27.5 – 56.5) 61.5 (54.0 – 68.8) 0.033*
Gender (male/female, %) 9 (90%)/1 (10%) 32 (89%)/4 (11%) >0.999
Etiology (HBV/HCV/Alcohol/Unknown, %)
8 (80%)/0 (0%)/0 (0%)/ 
2 (20%)
23 (64%)/1 (3%)/7 (19%)/ 
5 (14%)
0.438
Cirrhosis (%) 5 (50%) 10 (28%) 0.257
Serum AST (IU/L, median, IQR) 61.0 (33.0 – 105.0) 31.0 (22.3 – 35.0) 0.298
Serum ALT (IU/L, median, IQR) 27.0 (15.0 – 50.0) 28 (18.3 – 47.5) 0.723
Serum alpha-fetoprotein
(IU/mL, median, IQR) 299.8 (39.1 – 43872.5) 9.4 (3.3 – 35.4) 0.200
Serum PIVKA-II
(AU/mL, median, IQR) 329 (643.0 – 1606.0) 38.5 (20.3 – 1211.3) 0.066
Tumor pathology in resected specimens
Tumor number 
(one / two / three, %)
10 (100%)/0 (0%)/0 (0%) 31 (86%)/4 (11%)/1 (3%) 0.459
Diameter of entire tumor 
(cm, median, IQR) 7.0 (5.0 – 11.5) 4.0 (3.0 – 6.8) 0.134
Viable tumor area 
(cm2, median, range) 2.6 (0.8 – 27.0) 8.8 (1.2 – 110.4) 0.003
*
Differentiation
(Edmonson-Steiner Grade I/II/III, %)
2 (20%)/1 (10%)/7 (70%) 4 (11%)/23 (64%)/9 (25%) 0.009*
Presence of tumor necrosis (%) 10 (100%) 20 (56%) 0.002*
Proportion of tumor necrosis area to entire 
tumor region (%, median, IQR)
80.0 (67.5 – 95.0) 0 (0 – 10.0) <0.001*
Microvascular invasion (%) 8 (70%) 15 (42%) 0.071
Tumor capsule formation (%) 7 (70%) 22 (61%) 0.723
Serosal invasion (%) 7 (70%) 24 (67%) >0.999
TNM stage (stage I / II / III, %) 2 (20%)/8 (80%)/0 (0%) 19 (53%)/16 (44%)/1 (3%) 0.134
Immunomarker expression in biopsied specimens
K19 5 (50%) 11 (31%) 0.283
EpCAM 6 (60%) 12 (33%) 0.157
CD133 3 (30%) 9 (25%) 0.706
CAIX 3 (30%) 10 (28%) >0.999
VEGF 7 (70%) 28 (78%) 0.682
α-SMA 6 (60%) 25 (69%) 0.573
FAP 5 (50%) 19 (53%) 0.876
Immunomarker expression in resected specimens
K19 5 (50%) 10 (28%) 0.257
EpCAM 8 (80%) 14 (39%) 0.032*
CD133 6 (60%) 13 (36%) 0.277
CAIX 6 (60%) 10 (30%) 0.074
VEGF 6 (60%) 29 (81%) 0.220
α-SMA 9 (90%) 15 (42%) 0.011*
FAP 9 (90%) 19 (53%) 0.064
Abbreviations: HCC, hepatocellular carcinoma; TACE, transarterial chemoembolization; IQR, interquartile range;  HBV, hepatitis B 
virus; HCV, hepatitis C virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; PIVKA-II,  protein induced by vitamin 
K absence or antagonist II; TNM, tumor-node-metastasis; K19, keratin 19; EpCAM, epithelial cell adhesion molecule; CAIX, carbonic 
anhydrase IX; VEGF, vascular endothelial growth factor; α-SMA, α-smooth muscle actin; FAP, fibroblast activation protein. *P < 0.05
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In addition, it remains unclear whether the extent 
of K19, EpCAM and CAIX expression is constant or 
changed under TACE-induced hypoxia. To address 
this question, the sequential change in the degree of 
immunoexpression between biopsied and resected 
HCCs was evaluated and compared between HCCs of 
the TACE and non-TACE groups. Although there was 
extensive tumor necrosis (up to 95%, median 80%) in 
HCCs of TACE group, the viable tumor area ranged 
from 0.8 cm2 to 27.0 cm2 (median, 2.6 cm2). Therefore, 
the immunoprofiles of the viable tumor in TACE group 
were considered to be representative. While there was 
no significant difference in stemness-related marker 
expression status in the baseline preoperative biopsies 
of both groups, the sum of score change for stemness 
markers was significantly higher in the TACE group 
HCCs compared to the non-TACE group. Therefore, 
it is suggested that stemness marker expression may 
be increased in HCCs under TACE-induced hypoxic 
conditions. Taken together, we discerned that HCC tumor 
cells expressing stemness markers, which are considered 
as CSCs, may have a survival advantage in hypoxic tumor 
environment induced by TACE, and that these tumor 
cells may proliferate under TACE-induced hypoxia, as 
evidenced by the increased tumor extent of stemness-
related marker expression in this study. In addition, the 
degree of K19 expression was correlated with that of 
CAIX expression in resected HCCs. Accordingly, CAIX 
was reported to increase extracellular acidity and result 
in metabolic reprogramming, and maintenance of CSCs 
in breast cancer and prostate cancer [14, 35]. 
We found that the sequential change in sum 
of hypoxia marker (CAIX and VEGF) expression in 
matched biopsied and resected HCC was greater in TACE 
group than in non-TACE group, suggesting that hypoxic 
condition increased after TACE. However, there were no 
significant differences in CAIX and VEGF expression 
between resected HCCs of TACE and non-TACE group. 
It could be speculated that large sized HCCs in the TACE 
group had already adapted to the hypoxic condition 
caused by the imbalance between rapid growth and 
blood supply before TACE. Accordingly, CD34-positive/
VEGF-negative HCCs have been reported to be resistant 
to TACE-induced hypoxia, as they had already developed 
a sufficient vascular network without requiring further 
neoangiogenesis [36].
Figure 2: Sum of score changes of (A) stemness markers (K19, EpCAM and CD133), (B) hypoxia markers (CAIX and VEGF), and (C) 
stromal markers (α-SMA and FAP) checked in matched biopsied and resected HCC are compared between HCCs with preoperative TACE 
and those without TACE. The red bar represents that the expression of markers is higher in resected HCCs compared biopsied HCCs, in 
contrast that the blue bar represents decreased expression in resected HCCs than in biopsied HCCs. Deeper color indicates greater change, 
and the grey bar represents no change. (D) The correlation between expression of stemness markers (K19, EpCAM, and CD133) and those 
of stromal markers (α-SMA and FAP) and hypoxia markers (CAIX and VEGF). The black, grey, and white bars represent high, low, and 
no expression, respectively. *P < 0.05
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Table 3: Univariate analysis for overall survival in the non-TACE group HCCs (n = 36)
Overall survival (%)
Event / Total number 3-year 5-year P value
Clinical data collected at the time of biopsy
Age <60 years 8/16 69% 56% 0.885
≥60 years 8/20 69% 63%
Gender Male 14/32 68% 60% 0.980
Female 2/4 75% 50%
Etiology (Hepatitis B) HBV 7/13 78% 69% 0.138
Others 9/23 52% 42%
Serum alpha-fetoprotein <400 IU/mL 12/30 65% 61% 0.535
≥400 IU/mL 4/6 67% 50%
Serum PIVKA-II <400 AU/mL 6/20 79% 73% 0.347
≥400 AU/mL 4/8 63% 47%
Immunoprofiles in biopsied specimens
K19 Negative 8/25 79% 74% 0.011*
Positive 8/11 36% 27%
EpCAM Negative 10/24 74% 64% 0.667
Positive 6/12 58% 50%
CD133 Negative 12/27 65% 56% 0.749
Positive 4/9 78% 67%
CAIX Negative 9/26 80% 68% 0.023*
Positive 7/10 34% 34%
VEGF Negative 1/8 86% 86% 0.039*
Positive 15/28 63% 50%
α-SMA Negative 2/11 91% 91% 0.045*
Positive 14/25 59% 46%
FAP Negative 5/17 82% 75% 0.074
Positive 11/19 56% 45%
Pathological features and immunoprofiles in resected specimens 
Tumor size <5cm 7/22 77% 71% 0.112
≥5cm 9/14 57% 41%
Tumor multiplicity Single 13/31 66% 59% 0.765
Multiple 3/5 80% 53%
Differentiation (Edmonson-
Steiner grade)
Grade I/II 12/27 70% 62% 0.850
Grade III 4/9 65% 52%
Microvascular invasion Negative 6/21 79% 74% 0.024*
Positive 10/15 47% 40%
TNM stage Stage I 5/19 83% 70% 0.038*
Stage II/III 11/17 53% 46%
Cirrhosis None 12/26 65% 56% 0.671
Present 4/10 79% 68%
K19 Negative 8/26 80% 71% 0.007*
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Abundant intratumoral fibrous stroma is not a typical 
feature of HCC; we previously reported that HCCs with 
this feature exhibited high expression of stemness markers 
with upregulated transforming growth factor-β (TGF-β) 
signaling and epithelial-mesenchymal transition (EMT) 
regulators [37]. Recently, tumor stromal cells were reported 
to promote cancer cells to gain CSC properties through 
production of IL-6 or TGF-β1-induced EMT [38, 39]. 
FAP was shown to increase stromal cell proliferation and 
invasiveness, to reduce apoptosis, and to be associated with 
worse prognosis in colon cancer and pancreatic cancer [40, 
41]. In this study, the expression score difference of stromal 
markers (α-SMA and FAP) between preoperative biopsied 
and resected HCCs was significantly higher in TACE 
group HCCs compared with the non-TACE group. α-SMA 
expression was also higher in resected TACE group HCCs 
compared to non-TACE group HCCs, while there was no 
significant difference in α-SMA expression status in the 
baseline preoperative biopsied HCCs between two groups. 
Taken together, TACE-induced hypoxia is considered to 
Positive 8/10 40% 30%
EpCAM Negative 8/22 81% 70% 0.214
Positive 8/14 50% 43%
CD133 Negative 10/23 72% 63% 0.568
Positive 6/13 62% 53%
CAIX Negative 8/26 88% 75% 0.001*
Positive 8/10 20% 20%
VEGF Negative 2/7 83% 67% 0.372
Positive 14/29 65% 57%
α-SMA Negative 9/21 82% 69% 0.124
Positive 7/15 56% 50%
FAP Negative 4/17 81% 73% 0.038*
Positive 12/19 58% 47%
Abbreviations: HCC, hepatocellular carcinoma; TACE, transarterial chemoembolization; HBV, hepatitis B virus; PIVKA-II,  
protein induced by vitamin K absence or antagonist II; K19, keratin 19; EpCAM, epithelial cell adhesion molecule; 
CAIX, carbonic anhydrase IX; VEGF, vascular endothelial growth factor; α-SMA, α-smooth muscle actin; FAP, fibroblast 
activation protein. *P < 0.05
Figure 3: Kaplan-Meier survival curve representing the overall survival of hepatocellular carcinoma patients according to K19, CAIX, 
VEGF, α-SMA and FAP expression detected in (A) biopsied and (B) resected HCCs in non-TACE group. Positive expression is indicated 
by a dotted line, and negative expression is indicated by a solid line. *P < 0.05
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alter tumor stroma, which may in turn contribute to the 
aggressiveness of HCCs.
Crosstalk between the tumoral epithelia and 
stroma has been shown to facilitate tumor growth and 
cancer progression through EMT, in which TGF-β/ 
platelet-derived growth factor signaling plays a crucial 
role [42]. Interestingly, we found a positive correlation 
between the expression of stemness markers and 
stromal markers. Therefore, CSCs are not considered 
to be a fixed cell population and their plasticity might 
be regulated by tumor stromal factors, and the altered 
tumor stroma in hypoxia might provide a niche for 
CSC to proliferate in the residual HCC after TACE. 
In fact, CD133 transcription has been reported to be 
induced by IL-6/STAT3 signaling through functional 
cooperation with NF-κB and HIF-1α during liver 
carcinogenesis [43]. 
This is the first study to comprehensively 
evaluate the changes in immunoprofiles of tumor cells 
and tumor stroma after TACE using matched biopsied 
and resected HCCs. One of the limitations of this 
study is the small number of biopsy-resection matched 
cases. It is difficult to procure a large cohort of biopsy-
resection matched HCCs, as biopsy confirmation is 
not recommended for HCC when imaging findings 
are diagnostic according to the current guidelines. 
Survival analysis was not conducted separately for the 
TACE and non-TACE groups, due to the small number 
of biopsy-resection matched cases. Further studies 
based on a larger number of cases from multiple 
centers are required.
In conclusion, the expression of stemness markers 
is considered to be increased along with alteration of 
tumor stroma under TACE-induced hypoxia, which might 
promote the aggressive biology of HCC. Therefore, 
checking the expression status of these markers in 
biopsied HCCs may help to predict a poor outcome of 
HCCs, especially for TACE treatment. 
MATERIAL AND METHODS
Case selection and clinicopathologic analysis 
The study subjects comprised 46 patients who were 
diagnosed as HCC by preoperative biopsies and underwent 
subsequent surgical resection at Severance Hospital from 
January 2001 to February 2014. All preoperative baseline 
biopsies were taken prior to any treatment. After the 
biopsy, 10 cases underwent preoperative TACE (“TACE 
group”) and the remaining 36 cases received no TACE 
(“non-TACE group”). In all cases with multiple tumors 
(5 cases in non-TACE group, none in TACE group), 
the biopsy was performed from the largest nodule. 
Subsequently, the 46 patients received surgical resection 
of the HCCs. TACE, containing lipiodol with adriamycin 
or doxorubicin, was performed once in seven cases, twice 
in two cases, and three times in one case. The average 
intervals between biopsy and resection for the non-TACE 
group and TACE group were 72 days (range, 6 ~ 1039 
days) and 65 days (range, 16 ~ 247 days), respectively. 
Cases that underwent other types of treatment, such as 
radiofrequency ablation or chemotherapy, were excluded, 
and cases with total necrosis after TACE were also not 
included in this study, as their tumor immunoprofiles 
could not be assessed.
Histopathologic analysis was performed for 
tumor number, diameter of entire tumor, viable tumor 
area, differentiation (Edmondson-Steiner grade), tumor 
capsule formation, serosal invasion, microvascular 
invasion, presence of tumor necrosis, and proportion 
of tumor necrosis area to entire tumor region. In the 
cases with multiple tumors, histopathologic analysis 
was performed from the largest nodule. Tumor-
node-metastasis (TNM) classification was analyzed 
according to the 7th American Joint Committee on 
Cancer/International Union against Cancer (AJCC/
UICC) staging system. Clinical data, including age, sex, 
etiology, cirrhosis, serum aspartate aminotransferase 
(AST), serum alanine aminotransferase (ALT), serum 
alpha-fetoprotein (AFP), and serum protein induced 
by vitamin K absence or antagonist II (PIVKA-II), and 
follow up data were obtained from the electronic medical 
records. The mean follow-up period after resection was 
60.5 months (range, 2.5 ~ 142.4 months). This study was 
approved by the Institutional Review Board of Severance 
Hospital, Yonsei University College of Medicine (Seoul, 
Korea), and the need for patient consent was waived 
(4–2016–0826). 
Table 4: Multivariate analysis for overall survival in the resected HCCs of non-TACE group (n = 36)
Variables Multivariate analysis
Hazard ratio (95% CI) P value
CAIX (positive) 6.3 (2.1 – 19.2) 0.001*
FAP (positive) 4.1 (1.2 – 13.6) 0.022*
Abbreviations: HCC, hepatocellular carcinoma; TACE, transarterial chemoembolization; CAIX, carbonic anhydrase IX; 
FAP, fibroblast activation protein. *P < 0.05
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Immunohistochemical evaluation
Representative blocks of formalin-fixed paraffin 
embedded tissues were used for immunohistochemical 
stains. In the case of multiple nodules, we performed 
the immunohistochmical staining in the largest nodule, 
which was matched with biopsied HCC.  Details of 
the antibodies used are summarized in Table 5, and 
immunohistochemistry was performed as previously 
described [9]. K19, EpCAM, CD133, CAIX and VEGF 
were stained in the tumor epithelial cells, whereas 
α-SMA and FAP were stained in the cancer associated 
fibroblasts (CAFs) of tumor stroma. The positive 
expression area was defined as a percentage of the total 
tumor area, and the intensity of staining was evaluated as 
follows: 1, weak; 2, moderate; or 3, strong. Final scores 
were obtained by multiplying the positive expression 
area (%) by intensity, and divided into negative group 
(score 0), and positive group of low expression (1+) and 
high expression (2+). For stemness-related and hypoxia 
markers (K19, EpCAM, CD133, CAIX and VEGF), 
negative (0) was defined as scores <1 in biopsied and <5 
in resected HCCs, low expression (1+) was defined as 
scores 1 ~ 50 in biopsied and 5 ~ 50 in resected HCCs, 
and high expression (2+) was defined as score >50 in 
both biopsies and resection. For stromal markers (α-SMA 
and FAP), negative (0) was defined as scores <5 in 
biopsied and <10 in resected HCCs, low expression (1+) 
was defined as scores 5 ~ 20 in biopsies and 10 ~ 20 in 
resected HCCs, while high expression (2+) was defined 
as score >20 in both types of specimen. 
In order to evaluate the sequential change in the 
expression status of each marker between the biopsies and 
resected specimens, we calculated the differences between 
the expression scores of each marker in the biopsies and 
matched resected specimens (“score change”), and then 
added the differences of each markers to yield the “sum 
of score change”. For example, if K19 expression was 
low (1+) in the biopsy and high (2+) in the matched 
resected specimen, the score change was 1. In a similar 
manner, if the same patient showed low EpCAM (1+) 
and low CD133 (1+) expression in the biopsy, and high 
EpCAM (2+) and low CD133 (1+) in the resected tumors, 
the score changes were 1 and 0, respectively. The sum 
of score change was therefore 2 (1 + 1 + 0). The same 
method was applied for the hypoxia-related markers and 
stromal markers. The staining results were assessed by two 
pathologists unaware of the clinicopathological data for 
each case (Figure 1A). 
Statistical methods
Statistical analyses were carried out using SPSS 
software (version 21.0, SPSS Inc., Chicago, Illinois). 
Chi-square test or Fisher’s exact test was used. Univariate 
survival analyses were performed by the Kaplan-Meier 
method with log-rank test, and multivariate survival 
analyses were conducted by Cox regression with forward 
conditional method. Statistical significance was assumed 
when P < 0.05.
Table 5: Information on primary antibodies 
Antibody Source Clone Dilution Antigen retrieval Blocking
K19 Dako(Glostrup, Denmark) RCK108 1:25
Protease K 
(Dako, Glostrup, Denmark)
     -
EpCAM Calbiochem (Darmstadt, Germany) VU-1D9 1:3000 Microwave, citrate (pH 6.0)
     -
CD133
Miltenyi Biotech 
(Bergisch Gladbach, 
Germany)
W6B3C1 1:25 Microwave, citrate (pH 6.0) 2% BSA for 0.5h at RT
CAIX Abcam (Cambridge, UK) rabbit polyclonal 1:2000 Microwave, citrate (pH 6.0) 5% BSA for 5h at RT
VEGF
Santa Cruz Biotechnology 
(Dallas, TX, USA)
C-1 1:25 No treatment
α-SMA
Dako (Glostrup, 
Denmark) 1A4 1:1000 No treatment      -
FAP
Vitatex 
(Stony Brook, NY, USA)
Seprase D8 1:100 Microwave, citrate (pH 6.0)
Abbreviations: K19, keratin 19; EpCAM, epithelial cell adhesion molecule; CAIX, carbonic anhydrase-IX; VEGF, 
vascular endothelial growth factor; α-SMA, α-smooth muscle actin; FAP, fibroblast activation protein; BSA, bovine serum 
albumin; RT, room temperature.
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Abbreviations
HCC, hepatocellular carcinoma; CSC, cancer 
stem cell; K19, keratin 19; EpCAM, epithelial cell 
adhesion molecule; CD133, cluster of differentiation 
133; α-SMA, α-smooth muscle actin; FAP, fibroblast 
activation protein; HIF, hypoxia inducible factor; CAIX, 
carbonic anhydrase IX; VEGF, vascular endothelial 
growth factor; H&E, hematoxylin-eosin; TACE, transarterial 
chemoembolization; AST, aspartate aminotransferase; ALT, 
alanine aminotransferase; AFP, alpha-fetoprotein;  PIVKA-
II,  protein induced by vitamin K absence or antagonist II.
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